Longitudinal Study of Neurodegenerative Disorders
study id #: NCT03333200
condition: MLD, Krabbe Disease, ALD, MPS I, MPS II, MPS III, Vanishing White Matter Disease, GM3 Gangliosidosis, PKAN, Tay-Sachs Disease, NP Deficiency, Osteopetrosis, Alpha-Mannosidosis, Sandhoff Disease, Niemann-Pick Diseases, MPS IV, Gaucher Disease, GAN, GM1 Gangliosidoses, Morquio Disease, S-Adenosylhomocysteine Hydrolase Deficiency, Batten Disease, Pelizaeus-Merzbacher Disease, Leukodystrophy, Lysosomal Storage Diseases, Purine Nucleoside Phosphorylase Deficiency, Multiple Sulfatase Deficiency Disease
status: Recruiting
purpose:The purpose of this study is to understand the course of rare genetic disorders that affect the brain. This data is being analyzed to gain a better understanding of the progression of the rare neurodegenerative disorders and the effects of interventions.
intervention: Palliative Care, Hematopoetic Stem Cell Transplantation
results: https://clinicaltrials.gov/ct2/show/results/NCT03333200
last updated: February 26, 2022
-
Damage of the Cardiovascular System in Lysosomal Storage Disease – MucopolysaccharidosisThe analysis of literature data reflecti...
-
Mucopolysaccharidosis Market: Global Industry Analysis and Opportunity Assessment 2022-2029The wide ranging Mucopolysaccharidosis M...
-
CHOC-Harbor UCLA MPS Multidisciplinary CenterCHOC and Harbor-UCLA Pediatrics together...
-
MPS I: Early Diagnosis, Bone Disease and Treatment, Where Are We NowMucopolysaccharidosis type I (MPS I) is ...
-
Evaluation of the Long-Term Treatment Effects of Intravenous Idursulfase in Patients With Mucopolysaccharidosis II (...Mucopolysaccharidosis II (MPS II; Hunter...
-
Medical Travel Assistance Program (MTAP)Program provides financial assistance of...
-
Mucopolysaccharidosis II (MPS II) in a Free-Living Kaka (Nestor Meridionalis) in New ZealandA lysosomal storage disease, identified ...